ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1020

Screening Tools for Spondyloarthritis in Patients with Psoriasis, IBD, and Uveitis – A Scoping Review

Vartika Kesarwani1, Stephanie Sinnappan2, M. Elaine Husni3, Michael Weisman4 and Joerg Ermann5, 1University of Connecticut, Farmington, CT, 2Brigham and Women's Hospital, Boston, MA, 3Cleveland Clinic, Cleveland, OH, 4Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, Los Angeles, CA, 5Brigham and Women's Hospital, Harvard Medical School, Boston, MA

Meeting: ACR Convergence 2022

Keywords: spondyloarthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster II

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Extra-articular manifestations of spondyloarthritis (SpA) may precede the development of articular features. Patients seen in dermatology, gastroenterology, and ophthalmology clinics for psoriasis, IBD, or uveitis may have undiagnosed SpA. The goal of this review was to assess the available evidence and compare the design of existing screening tools for SpA in patients with psoriasis, IBD, and uveitis. We further sought to identify relevant factors that may influence the performance of these instruments and aid in developing more robust SpA screening tools in the future.

Methods: We followed the PRISMA guideline extension for scoping reviews. We searched PubMed, EMBASE, and Web of Science from inception to January 2022. Two independent reviewers identified and screened the studies for eligibility. Data regarding the study type, development method, characteristics of the screening tool, and the performance parameters were extracted.

Results: Fifty-two studies were included. Eighteen were descriptions of new screening tools, 23 were validation studies, 8 were comparative analyses of previously described tools, and 3 were systematic reviews. We identified 13 screening tools for PsA, 3 tools for SpA screening in IBD, and 2 tools for SpA screening in uveitis (Table 1). Most tools were developed using expert opinion and literature review. PEST, pAsQ, CONTEST, SiPAT, SiPAS, and STRIPP were formulated by combining previously described tools. Only PASE and IBIS-Q used patient input in the development phase.

Almost all screening tools are questionnaires to be completed by the patients. A single tool, DUET, is an algorithm applied by a physician. The median number of items included was 6 (range 3 – 16). Most tools use simple yes/no questions. The PASE uses a five-point Likert scale, and PsA-Disk uses an 11-point numerical scale. The screening tools showed variability in identifying different features of SpA (Table 2). Three of the 18 tools used visual aids such as mannequins or photographs (Table 3). The completion time was reported for 5 of the 18 tools with an average of < 5 minutes. The sensitivity and specificity of all the screening tools were largely equivalent in the development cohorts ranging from 83 to 97% and 71 to 97%, respectively. The sensitivity and specificity were generally lower in the subsequent validation studies.

Conclusion: There is no single SpA screening tool that can be applied to all patients with any extra-articular manifestation. Most screening tools were for PsA with a paucity of SpA screening tools for patients with IBD or uveitis. Not all tools screened for axial involvement. We conclude that an ideal screening tool should include questions related to axial involvement, peripheral arthritis, enthesitis, and dactylitis. It might be possible to improve performance by eliminating questions not specific to inflammatory arthritis, including most discriminatory questions, and utilizing visual aids to improve agreement between doctors and patients. Patient-focused screening tools need to be easy to understand and quickly completed by the patient during the clinic visit before provider engagement.

Supporting image 1

Table 1: SpA screening tools in patients with psoriasis, IBD, and uveitis. *2 questionnaires consisted of 3 questions each for axial and peripheral inflammatory arthritis: **Inflammatory back pain.

Supporting image 2

Table 2: Analysis of questions included in the screening tools.

Supporting image 3

Table 3: Visual aids used in the screening tools.


Disclosures: V. Kesarwani, None; S. Sinnappan, None; M. Husni, AbbVie, Amgen, BMS, Eli Lilly, Janssen, Novartis, Pfizer, UCB Pharma; M. Weisman, None; J. Ermann, Novartis, Pfizer, AbbVie/Abbott, UCB, Eli Lilly.

To cite this abstract in AMA style:

Kesarwani V, Sinnappan S, Husni M, Weisman M, Ermann J. Screening Tools for Spondyloarthritis in Patients with Psoriasis, IBD, and Uveitis – A Scoping Review [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/screening-tools-for-spondyloarthritis-in-patients-with-psoriasis-ibd-and-uveitis-a-scoping-review/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/screening-tools-for-spondyloarthritis-in-patients-with-psoriasis-ibd-and-uveitis-a-scoping-review/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology